The Anticholinergic Drug Effect on Decreasing Cognitive in Geriatric Patients at Kota Surakarta General Hospital
Nurlena Ikawati(1*), Fita Rahmawati(2)
(1) Graduate Program of Faculty of Pharmacy, Universitas Gadjah Mada
(2) Faculty of Pharmacy, Universitas Gadjah Mada
(*) Corresponding Author
Abstract
Keywords
Full Text:
PDFReferences
Kersten H, Wyller TB. Anticholinergic Drug Burden in Older People’s Brain - How well is it Measured? Basic Clin Pharmacol Toxicol. 2014;114(2):151-159. doi:10.1111/bcpt.12140.
Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics : A clinical review. Clin Interv Aging. 2009;4:225-233.
Lampela P, Paajanen T, Hartikainen S, Huupponen R. Central Anticholinergic Adverse Effects and Their Measurement. Drugs and Aging. 2015;32(12):963-974. doi:10.1007/s40266-015-0321-6.
Lo Coco D, Lopez G, Corrao S. Cognitive impairment and stroke in elderly patients. Vasc Health Risk Manag. 2016;12:105-116. doi:10.2147/VHRM.S75306.
Carpenter CR, Despain B, Keeling TN, Shah M, Rothenberger M. The six-item screener and AD8 for the detection of cognitive impairment in geriatric emergency department patients. Ann Emerg Med. 2011;57(6):653-661. doi:10.1016/j.annemergmed.2010.06.560.
Cai X, Campbell N, Khan B, Callahan C, Boustani M. Long-term anticholinergic use and the aging brain. Alzheimer’s Dement. 2013;9(4):377-385. doi:10.1016/j.jalz.2012.02.005.
Jacob S. Polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in Malaysia. Ment Heal Fam Med. 2013;10:37-43.
Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc. 2015;63(1):85-90. doi:10.1111/jgs.13206.
Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481-1486. doi:10.1177/0091270006292126.
Johnell K, Fastbom J. Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients. Drugs Aging. 2008;25(10):871-877. doi:25106 [pii].
Persaud M, Holroyd-Leduc JM. Anticholinergic medications in the older adult: A hidden burden. Can Geriatr Soc J C. 2014;4(2):4-7. www.cmegeriatrics.ca.
He Z, Ball PA. Can medication management review reduce anticholinergic burden (ACB) in the elderly? Encouraging results from a theoretical model. Int Psychogeriatrics C Int Psychogeriatr Assoc. 2013;25(9):1425-1431. doi:10.1017/S1041610213000872.
Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications. Expert Rev Neurother. 2008;8(11):1703-1718. doi:10.1586/14737175.8.11.1703.
Kar S, Slowikowski SPM, Westaway D, Mount HTJ. Interactions between β-amyloid and central cholinergic neurons : implications for Alzheimer ’ s disease. J Psychiatry Neurosci. 2014;29(6):427-442.
Shah RC, Janos AL, Kline JE, et al. Cognitive Decline in Older Persons Initiating Anticholinergic Medications. PLoS One. 2013;8(5):4-9. doi:10.1371/journal.pone.0064111.
Salahudeen MS, Hilmer SN, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;63(1):85-90. doi:10.1111/jgs.13206.
DOI: https://doi.org/10.22146/jmpf.33257
Article Metrics
Abstract views : 1266 | views : 46442Refbacks
- There are currently no refbacks.
Copyright (c) 2018 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.